HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock

Enlivex Therapeutics (NASDAQ:ENLV) had its price target raised by research analysts at HC Wainwright from $13.00 to $20.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

A number of other research firms have also recently commented on ENLV. Weiss Ratings restated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. Wall Street Zen cut shares of Enlivex Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Enlivex Therapeutics has a consensus rating of “Hold” and a consensus price target of $16.50.

Enlivex Therapeutics Trading Down 8.2%

NASDAQ ENLV opened at $0.87 on Tuesday. The company’s 50-day moving average price is $1.09 and its 200-day moving average price is $1.02. The stock has a market cap of $207.38 million, a PE ratio of -1.59 and a beta of 1.68. Enlivex Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in Enlivex Therapeutics during the 4th quarter worth about $33,000. Invesco Ltd. bought a new position in Enlivex Therapeutics during the 4th quarter worth about $43,000. XTX Topco Ltd boosted its holdings in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after buying an additional 19,132 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after buying an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Enlivex Therapeutics in the 3rd quarter valued at about $57,000. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.